>>> US Gapping up

Gapping up
In reaction to earnings/guidance:
  • MSM +1.6% ( beats by $0.05, reports revs in-line )
Other news:
  • ATAI +12.3% (and Beckley Psytech announce positive topline results from the phase 2B study of BPL-003 in patients with treatment-resistant depression and announces $50 million private placement financing)
  • MESO +11.1% ( and FDA align on key items for Revascor biologic license application in ischemic heart failure)
  • ADAG +5.1% (announces up to $25 million strategic investment from Sanofi (SNY)
  • QBTS +5.1% ( announces successful completion of $400 million at-the-market equity offering)
  • METC +4.3% ( Independent preliminary economic assessment report from Fluor Corporation (FLR) confirms commercial and technical feasibility of Ramaco's brook mine rare earth deposit)
  • DGXX +3.2% ( reports 45% month-over-month increase in cash and crypto position with no long-term debt and reports June 2025 production results)
  • CANG +3.1% (announces June 2025 production update for crypto mining business )
  • INVX +3.1% (completes divestment of Subsea Tree Product Line )
  • CXDO +3% (Wholesale UCaaS Market Share Gainer; Initiate Buy and $8 PT -- Needham)
  • TOI +2.9% (will be exclusive Medicaid oncology provider for SilverSummit in Nevada),
  • APLS +2.8% (to receive up to $300 million from royalty purchase agreement with Sobi for Ex-U.S. royalties of Aspavel)
  • ACMR +2.7% (unit received registration approval from the China Securities Regulatory Commission for its proposed private offering of ordinary shares to qualified buyers)
  • IMAB +2.1% (Givastomig data published)
  • LEGN +1.9% ( confirmed the EMA published a recommendation for CARVYKTI to add sentence to the Summary of Product Characteristics (SmPC) special warnings and precautions )
  • ABEO +1.8% ( announces that Beacon Therapeutics has exercised its option to license Abeona's patented AAV204 capsid for use in potential gene therapies for a range of prevalent and rare retinal diseases that result in blindness)
  • VSTM +1.7% (Phase 1 FRAME study of Avutometinib published),
  • CRCL +1.6% (formally submits application to establish a national trust bank)
  • TPC +1.6% (awarded $1.871 bln NYC contract)
  • JBIO +1.6% (announces the appointment of Brad Dahms as Chief Financial Officer)
  • ULY +1.6% ( initiated with a Neutral at Chardan Capital Markets; tgt $15)
  • NEXA +1.2% (operations at smelter have fully resumed)
  • NIO +1.2% ( provides June and Q2 2025 delivery update )
  • CYBN +1.1% (announces financing of up to $500 million aggregate principal amount of convertible debentures)